Merus (NASDAQ:MRUS – Get Free Report) had its target price raised by equities researchers at Guggenheim from $46.00 to $48.00 in a report issued on Tuesday, MarketBeat reports. The firm currently has a “buy” rating on the biotechnology company’s stock. Guggenheim’s price objective would suggest a potential upside of 109.61% from the stock’s current price. […]
Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) – Equities researchers at HC Wainwright increased their Q3 2023 EPS estimates for Allogene Therapeutics in a report issued on Monday, August 7th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.48) per share for the quarter, up from their prior estimate […]
Bicycle Therapeutics plc (NASDAQ:BCYC – Get Free Report) has been given a consensus rating of “Moderate Buy” by the nine analysts that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average twelve-month price objective […]
Needham & Company LLC restated their buy rating on shares of Merus (NASDAQ:MRUS – Free Report) in a research note published on Tuesday, Benzinga reports. Needham & Company LLC currently has a $45.00 price objective on the biotechnology company’s stock. Several other analysts also recently commented on the stock. EF Hutton Acquisition Co. I restated […]
Needham & Company LLC Reaffirms Buy Rating for CRISPR Therapeutics (NASDAQ:CRSP) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.